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Abstract
Introduction: Both overt and subclinical hypothyroidism are often accompanied by sexual dysfunction. Despite improving male sexual 
functioning, levothyroxine treatment does not always restore all its aspects. The aim of this study was to compare male sexual function-
ing and depressive symptoms between men with hypothyroidism receiving levothyroxine/liothyronine combination therapy and men 
receiving levothyroxine alone.
Material and methods: The study population consisted of 21 young levothyroxine-treated men with clinical symptoms of hypothyroid-
ism, in whom serum thyrotropin and thyroid hormone levels were within the normal limits. In 11 of these patients, levothyroxine was 
replaced with levothyroxine/liothyronine combination therapy, while the remaining ones (n = 10) continued levothyroxine treatment. 
Beyond measuring serum levels of thyrotropin, free thyroxine, free triiodothyronine, and prolactin, before the beginning of the study and 
six months later, all enrolled patients completed questionnaires evaluating male sexual function (International Index of Erectile Func-
tion-15: IIEF-15) and assessing the presence and severity of depressive symptoms (Beck Depression Inventory-Second Edition — BDI-II). 
Results: The study included 10 patients from each group. At baseline, erectile function, intercourse satisfaction, orgasmic function, sexual 
desire and overall satisfaction, as well as the total BDI-II score did not differ between both groups. With the exception of an improvement 
in sexual desire, replacing levothyroxine with levothyroxine/liothyronine combination therapy did not affect sexual functioning and 
depressive symptoms.
Conclusions: The obtained results suggest that levothyroxine/liothyronine combination therapy has a relatively mild effect on sexual 
functioning in levothyroxine-treated men with normal thyrotropin and thyroid hormone levels experiencing clinical symptoms of hypo-
thyroidism. (Endokrynol Pol 2018; 69 (1): 16–22)
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Streszczenie
Wprowadzenie: Zarówno klinicznie jawnej jak i subklinicznej niedoczynności tarczycy często towarzyszy dysfunkcja seksualna. Pomimo 
poprawy, lewotyroksyna nie zawsze normalizuje funkcjonowanie seksualne w stanach niedoboru hormonów tarczycy. Celem badania 
było porównanie funkcjonowania seksualnego i objawów depresyjnych pomiędzy mężczyznami leczonymi zarówno lewotyroksyną 
i liotyroniną oraz mężczyznami otrzymującymi wyłącznie lewotyroksynę.
Materiał i metody: Uczestnikami badania było 21 mężczyzn leczonych lewotyroksyną odczuwających objawy kliniczne niedoczynności 
tarczycy, pomimo mieszczących się w granicach normy stężeniach TSH i wolnych hormonów tarczycy. U 11 z nich w miejsce lewoty-
roksyny włączono preparat skojarzony zawierający lewotyroksynę i liotyroninę, podczas gdy pozostałych 10 pacjentów kontynuowało 
leczenie lewotyroksyną. Poza oceną stężenia w surowicy: TSH, wolnej tyroksyny, wolnej trijodotyroniny i prolaktyny, w dniu rozpoczęcia 
badania i sześć miesięcy później, wszyscy pacjenci wypełniali kwestionariusze oceniające funkcjonowanie seksualne (IIEF-15), jak również 
obecność i nasilenie objawów depresyjnych (BDI-II). 
Wyniki: W każdej grupie badanie ukończyło dziesięciu pacjentów. W warunkach wyjściowych funkcja erekcyjna, satysfakcja seksualna, 
jakość orgazmu, pożądanie, całkowita satysfakcja seksualna, jak również globalny wskaźnik BDI-II nie różniły się między grupami. Za 
wyjątkiem poprawy w zakresie libido, zastąpienie lewotyroksyny leczeniem skojarzonym nie wpływało na funkcjonowanie seksualne 
i objawy depresyjne. 
Wnioski: Uzyskane wyniki sugerują, iż terapia skojarzona lewotyroksyną i liotyroniną ma stosunkowo niewielki wpływ na funkcjono-
wanie seksualne mężczyzn odczuwających objawy niedoczynności tarczycy pomimo prawidłowego stężenia TSH i hormonów tarczycy. 
(Endokrynol Pol 2018; 69 (1): 16–22)
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Introduction
Impaired sexual functioning is frequently observed in 
men with thyroid disorders. Erectile dysfunction has 
been reported more frequently in men with either hypo-
thyroidism or hyperthyroidism than in men with normal 
thyroid function [1, 2], but after adjusting for potential 
confounders only frank hyperthyroidism was found to 
be associated with erectile dysfunction [3]. Unlike erectile 
function, libido was more disturbed in men with hypo-
function than in men with hyperfunction of the thyroid 
gland [1, 4]. Moreover, hypothyroidism often results in 
delayed ejaculation, while elevated thyroid hormone 
levels are frequently accompanied by premature ejacula-
tion [1, 5, 6]. Finally, hypothyroidism was found to impair 
sperm count, morphology, and motility [7], while hyper-
thyroidism leads to low total sperm count, lineal motility 
defects and progressive motility abnormalities [8]. Much 
less is known about the effect of treatment on various 
aspects of sexual functioning in men with thyroid disor-
ders. The restoration of normal hypothalamic-pituitary-
thyroid axis activity in men with hypothyroidism and 
hyperthyroidism improved erectile functioning [1, 2]. 
In our recent study [9], levothyroxine administered to pa-
tients with hypothyroidism produced a beneficial effect 
on the domains of male sexual functioning, the activity 
of which was disturbed, and the strength of this effect 
depended on the degree of thyroid hypofunction and 
thyroid autoimmunity. However, in patients with overt 
hypothyroidism post-treatment erectile functioning was 
still worse than in healthy subjects.
Despite biochemical euthyroidism, some hypothy-
roid patients receiving levothyroxine treatment report 
persisting symptoms of clinical hypothyroidism. There 
are conflicting animal and human data indicating that 
the addition of liothyronine to levothyroxine therapy 
may reverse these symptoms and improve quality of 
life [10, 11]. However, in some studies the combination 
therapy was found to bring benefits to patients with 
a low quality of life [12, 13].
To the best of our knowledge, no previous study has 
investigated the effect of liothyronine, administered 
alone or in combination with levothyroxine, on sexual 
functioning. Therefore, this study was aimed at compar-
ing whether replacing levothyroxine with levothyroxine/
liothyronine combination therapy affects sexual func-
tioning and depressive symptoms in young men expe-
riencing clinical symptoms of hypothyroidism in whom 
serum thyrotropin levels were within the normal limits.
Material and methods
This research study included young males (18–45 years 
old) who, because of hypothyroidism were treated 
with levothyroxine (75–150 µg/daily) for at least six 
months before the study onset. To be admitted to the 
study, they had to meet the following inclusion criteria: 
(a) the presence of at least three clinical symptoms of 
hypothyroidism (easy fatigue, loss of energy, weight 
gain, cold intolerance, dry skin, muscle pain, inability 
to concentrate, or constipation) and (b) normal thyroid 
function, defined as serum thyrotropin levels above 
0.4 but less than 4.5 mU/L, combined with serum levels 
of free thyroid hormones within the reference range. 
The exclusion criteria were as follows: hypo-
gonadism, prolactin-secreting tumours, diabetes, 
multiple sclerosis, prostatitis, psychiatric problems, 
cardiovascular disease, impaired renal or hepatic func-
tion, vasculogenic or neurogenic disorders known to 
impair sexual functioning, developmental or acquired 
anomalies of the male reproductive system, as well as 
previous operations that might have affected sexual 
function.
Before enrolment, all patients were informed about 
the benefits and harms of levothyroxine/liothyronine 
combination therapy and gave written, informed con-
sent to participate in the study. The study protocol was 
approved by our institutional Review Board.
On the basis of patient preference, the participants 
were then allocated to one of two groups. In the first 
one (n = 11), levothyroxine was replaced with levothy-
roxine/liothyronine combination therapy (a prepara-
tion containing both levothyroxine and liothyronine 
in a weight proportion of 5:1 (a molar proportion of 
4.2:1), while the second group (n = 10) continued 
treatment with the same daily dose of levothyroxine. 
Both levothyroxine/liothyronine combination therapy 
and levothyroxine alone were administered orally once 
daily, 30–60 minutes before breakfast for six months, 
without any changes in dosage throughout the study. 
Compliance with medication usage was assessed at 
each visit by interrogation and pill count.
All measurements were performed at baseline and 
at the end of the study. Venous blood samples were 
taken from the antecubital vein at 8 a.m. (12 hours after 
the last meal) in a quiet, temperature-controlled room 
(24–25°C). Serum levels of thyrotropin, free thyroxine, 
free triiodothyronine and prolactin were determined 
by direct chemiluminescence using acridinium ester 
technology (ADVIA Centaur XP Immunoassay System, 
Siemens Healthcare Diagnostics, Munich, Germany). 
All assays were performed in duplicate to minimise 
analytical errors.
Immediately after blood collection, all participants 
were asked to complete questionnaires assessing 
(a) their demographic characteristics, smoking, physi-
cal activity, education, occupation, stress exposure, the 
number of sexual partners, the number and duration 
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of marriages, as well as systolic and diastolic blood 
pressure; (b) sexual functioning for heterosexual men 
(the International Index of Erectile Function-15: IIEF-
15); and (c) depression severity (the Beck Depression 
Inventory Second Edition: BDI-II).
IIEF-15, a reliable, cross-culturally valid and psy-
chometrically sound measure of sexual functioning in 
men [14, 15], consists of 15 items divided into five col-
lective sexual domains evaluating various dimensions 
of male sexual functioning: erectile function (questions 
1 to 5 and 15), intercourse satisfaction (questions 6–8), 
orgasmic function (questions 9 and 10), sexual desire 
(questions 11 and 12), and overall satisfaction; from 
sexual activity (questions 13 and 14) in the last four 
weeks. Each answer is rated on a scale ranging from 0 to 
5 or 1 to 5 (higher scores are suggestive of better sexual 
function). Domain scores are obtained from the sum of 
the items in each domain. Minimum domain scores are: 
0 for intercourse satisfaction, and orgasmic function, 
1 for erectile function, and 2 for sexual desire and overall 
satisfaction, while maximum ones are: 10 for orgasmic 
function, sexual desire and overall satisfaction, 15 for 
intercourse satisfaction and 30 for erectile function. 
Erectile dysfunction, defined as an overall erectile func-
tion score less than 26, is classified as: severe (no more 
than 10), moderate (11–16), mild to moderate (17–21), 
or mild (22–25) [14, 15].
The BDI-II is a 21-item self-report questionnaire 
with items rated on a four-point Likert scale from 0 (not 
present) to 3 (severe) [16]. The questions are adjusted 
to correspond with the diagnostic criteria for depres-
sive disorders outlined in the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition [17]. The 
total score, being the sum of the individual scores, can 
range from 0 to 63. Higher total scores indicate more 
severe depressive symptoms. Based on the overall 
BDI-II score, depressive symptoms are classified as 
minimal (0–13), mild (14–19), moderate (20–28), or 
severe (29–63) [16].
Because of the skewed distributions, values were 
natural-log transformed to achieve a normal distribu-
tion. Comparisons between the groups were performed 
using Student’s t-test for independent samples. Stu-
dent’s paired t test was used to compare differences 
between the means of variables within the same group. 
Qualitative variables were compared using the c2 test. 
Pearson’s r-tests were used to test correlations. A prob-
ability value of p less than 0.05 was regarded as statisti-
cally significant.
Results
One patient receiving levothyroxine/liothyronine 
combination therapy was withdrawn from the study 
because of adverse effects (tachycardia, irritability, 
tremor and heat intolerance). The study finally included 
10 men receiving the combination therapy and 10 men 
treated with levothyroxine alone, and only the data of 
these patients were included in the final analyses.
At baseline, both groups of men were comparable 
with respect to age, smoking, education, physical activ-
ity, occupational activity, a type of work, the number of 
sexual partners, the number and duration of marriages, 
stress exposure, and blood pressure (Table I). The mean 
serum levels of thyrotropin, free thyroid hormones, 
and prolactin did not differ between the groups (Table 
II). There were no significant differences between both 
groups in baseline sexual functioning (Table III) and in 
depressive symptoms (Table IV). Mild to moderate and 
mild erectile dysfunction were found in one (10%) and 
three (30%) patients treated later with levothyroxine, 
as well as in one (10%) and three (30%) patients who 
were switched to the combination therapy. No cases of 
severe or moderate erectile dysfunction were reported.
In both treatment groups, the body mass index and 
systolic and diastolic blood pressure were similar on the 
first and in the last day of the study.
No changes in serum concentrations of all investi-
gated hormones were observed in patients who contin-
ued levothyroxine therapy. Levothyroxine/liothyronine 
combination therapy increased serum levels of free trii-
odothyronine and tended to decrease (P = 0.083) serum 
levels of thyrotropin. The combination therapy did not 
affect serum levels of free thyroxine and prolactin. At 
the end of the study, levels of free triiodothyronine were 
higher, while levels of thyrotropin tended to be lower 
(P = 0.092) in patients receiving the combination thera-
py than in those receiving levothyroxine alone (Table II). 
Continuation of levothyroxine treatment did not af-
fect any aspect of male sexual functioning (Table III), and 
did not affect the total BDI score and the percentage of 
patients with total, mild, moderate, and severe depres-
sive symptoms (Table IV). Replacing levothyroxine with 
levothyroxine/liothyronine improved sexual desire but 
did not affect erectile function, intercourse satisfaction, 
orgasmic function, and overall satisfaction. At the end of 
the study, both groups differed in sexual desire (Table III). 
The overall BDI-II score, as well as the percentage of 
men with total, mild, moderate, and severe depressive 
symptoms did not change throughout the study and at 
the end of the study did not differ between the groups 
(Table IV).
At study entry, erectile function, intercourse satis-
faction, orgasmic function, sexual desire and overall 
satisfaction inversely correlated with the overall BDI-
II score (r values between –0.27 [P < 0.05] and –0.40 
[P < 0.001]). Desire inversely correlated with serum 
thyrotropin levels (r = –0.30, P < 0.05) and serum 
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Table I. Sociodemographic characteristics of the study population 
Tabela I. Socjodemograficzna charakterystyka uczestników badania
Levothyroxine Levothyroxine/ 
/Liothyronine
Number of patients 10 10
Age [years; mean (SD)] 35 (6) 36 (5)
Body mass index [kg/m2; mean (SD)] 27.1 (2.3) 26.9 (2.5)
Smokers [%]/Number of cigarettes a day [n; mean (SD)]/Duration of smoking [months, 
mean (SD)]
30/12(5)/275 (53) 30/11(6)/284 (61)
Physical activity: total/once a week/several times a week/ once a month [%] 90/40/30/20 90/30/30/30
Primary or vocational/secondary/university education [%] 10/50/40 10/40/50
Occupational activity/blue-collar/white-collar/pink-collar workers [%] 100/50/50/0 100/60/40/0
Number of sexual partners [n; mean (SD)] 2.1 (1.1) 2.2 (1.0)
Number of marriages [n; mean (SD)]/ duration of marriages [months; mean (SD)] 1.0 (0.7)/65 (14) 1.1 (0.6)/70 (18)
Stress exposure [%, mean (SD)] 70 80
Systolic blood pressure [mm Hg; mean (SD)] 130 (15) 132 (12)
Diastolic blood pressure [mm Hg; mean (SD)] 82 (7) 83 (6)
Table II. The effect of thyroid hormone supplementation on serum hormone levels in men
Tabela II. Wpływ stosowania egzogennych hormonów tarczycy na stężenie hormonów w surowicy uczestników badania
Levothyroxine Levothyroxine/
Liothyronine
Thyrotropin [mIU/L; mean (SD)]
Baseline
At the end of the study
2.3 (0.8)
2.1 (0.8)
2.2 (0.7)
1.7 (0.6)
Free thyroxine [pmol/L; mean (SD)]
Baseline
At the end of the study
16.5 (2.5)
16.2 (2.8)
16.7 (3.0)
16.9 (3.1)
Free triiodothyronine [pmol/L; mean (SD)]
 Baseline
At the end of the study
4.5 (0.7)
4.4 (0.6)
4.3 (0.6)
5.1 (0.7)a,b
Prolactin [ng/mL; mean (SD)]
Baseline
At the end of the study
14 (5)
12 (5)
14 (7)
10 (5)
aP < 0.05 vs. baseline value; bP < 0.05 vs. the other group of patients
prolactin levels (r = –0.32, P < 0.05), and positively cor-
related with serum thyroxine (r = 0.24, P < 0.05) and 
triiodothyronine levels (r = 0.34, P < 0.05). Moreover, 
the BDI-II score correlated with the body mass index 
(r = 0.48, P < 0.001), as well as with systolic (r = 0.38, 
P < 0.01) and diastolic (r = 0.37, P < 0.01) blood pres-
sure. Combination therapy-induced changes in desire 
correlated with its effect on free triiodothyronine levels 
(r = 0.31, P < 0.05). No other correlations were found.
Discussion
This study shows for the first time that levothyroxine ad-
ministered together with liothyronine exhibits a slightly 
better effect on sexual functioning than levothyroxine 
administered alone, and that levothyroxine-treated men 
with hypothyroidism coexisting with impaired desire may 
benefit more from levothyroxine/liothyronine combina-
tion therapy than from levothyroxine monotherapy.
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Table III. The effect of thyroid hormone supplementation on sexual functioning in men
Tabela III. Wpływ stosowania egzogennych hormonów tarczycy na funkcjonowanie seksualne uczestników badania
Variable Levothyroxine Levothyroxine/ 
/Liothyronine
Erectile function [mean (SD)]
Baseline
At the end of the study
25.7 (2.8)
25.5 (2.9)
25.4 (3.7)
26.1 (2.3)
Erectile dysfunction [%]
Baseline
At the end of the study
40
40
40
30
Intercourse satisfaction [mean (SD)]
Baseline
At the end of the study
11.1 (2.4)
11.2 (1.5)
10.9 (2.0)
11.7 (1.9)
Orgasmic function [mean (SD)]
Baseline
At the end of the study
6.9 (1.4)
7.1 (1.6)
7.0 (1.6)
7.5 (1.2)
Sexual desire [mean (SD)]
Baseline
At the end of the study
7.0 (1.2)
7.2 (1.3)
7.2 (1.4)
8.5 (0.8)a, b
Overall satisfaction [mean (SD)]
Baseline
At the end of the study
7.3 (1.4)
7.4 (1.3)
7.5 (1.3)
7.9 (1.4)
aP < 0.05 vs. baseline value; bP < 0.05 vs. the other group of patients
Table IV. The effect of thyroid hormone supplementation on depressive symptoms in men
Tabela IV. Wpływ stosowania egzogennych hormonów tarczycy na objawy depresyjne uczestników badania
Variable Levothyroxine Levothyroxine/ 
/Liothyronine
BDI-II score [mean (SD)]
Baseline
At the end of the study
13.1 (3.1)
13.2 (3.2)
13.0 (2.7)
12.3 (2.4)
depressive symptoms [n (%)]
Baseline
At the end of the study
3 (30)
3 (30)
3 (30)
2 (20)
mild symptoms [n (%)]
Baseline
At the end of the study
3 (30)
3 (30)
3 (30)
2 (20)
moderate symptoms [n (%)]
Baseline
At the end of the study
0 (0)
0 (0)
0 (0)
0 (0)
severe symptoms [n (%)]
Baseline
At the end of the study
0 (0)
0 (0)
0 (0)
0 (0)
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The present findings are in contrast with our pre-
vious research, which showed that impaired erection 
was the only sexual dysfunction observed in men with 
subclinical hypothyroidism as well as a domain most se-
riously affected in patients with overt hypothyroidism 
[9]. Moreover, correlations between erectile functioning 
and thyrotropin and free thyroid hormone levels were 
stronger than for the remaining domains of IIEF-15 
[9]. These differences may reflect the direct impact of 
chronic levothyroxine treatment (participants of the 
previous study were levothyroxine-naïve) and/or dif-
ferent inclusion criteria. The previous study included 
men with biochemical hypothyroidism, suggesting 
hypothalamic-pituitary-thyroid axis hypofunction. 
The presence of clinical symptoms in the participants 
of the present study suggests that at least some of them 
were characterised by either low tissue levels of thyroid 
hormones and/or by impaired thyroid hormone ac-
tion at the level of the brain and/or peripheral tissues. 
This interpretation is in agreement with the results of 
animal studies [18, 19]. In thyroidectomised rats, levo-
thyroxine restored tissue content of thyroid hormones 
only in a few tissues and structures, (the cerebral cor-
tex, cerebellum, and brown adipose tissue). In order 
to restore euthyroidism in the remaining structures 
levothyroxine had to be administered together with 
liothyronine [18, 19].
In light of previous observations, the impact of 
levothyroxine/liothyronine combination therapy on 
male sexual functioning is undoubtedly interesting. 
Although no data are available for men, macroprol-
actinaemia and vitamin D insufficiency, representing 
mild endocrinopathies, were accompanied by isolated 
hypolibidaemia in women [20, 21]. In turn, more severe 
forms of prolactin excess and of hypovitaminosis D 
were associated with disturbances of other aspects of 
sexual functioning [20, 21]. What is more, irrespectively 
of gender, serum androgen levels correlated better 
with desire than with other domains of male and 
female sexual functioning [22–24]. This may suggest 
that discrete abnormalities in the production and/or 
metabolism of hormones playing a role in the regulation 
of sexual functioning secondary to tissue hypothyroid-
ism may, at least partially, explain the beneficial effect 
of levothyroxine/liothyronine combination therapy in 
our study. In line with this hypothesis, hypothyroid 
rats were characterised by a decreased number and 
impaired morphology of Leydig cells [25], while thyroid 
hormone supplementation increased testicular testos-
terone production [25, 26]. Certainly, it cannot be ruled 
out that impaired desire may be a consequence of an 
effect on cardiovascular homeostasis and/or on nervous 
regulation of the sexual response [27, 28].
The molar proportion of thyroxine to triiodothyro-
nine (4.2:1) in a preparation used in the present study 
reflects serum levels of both hormones. However, it is 
lower than the molar proportion of daily secretion of 
thyroxine and triiodothyronine (14:1) by the human 
thyroid gland [20, 29]. This fact suggests a relative 
excess of liothyronine, which, unlike levothyroxine, 
is characterised by a short half-life, leading to widely 
varying serum levels of this hormone [30]. Taking 
into account the presence of correlations between the 
impact of the combination therapy on desire and on 
free triiodothyronine levels, we may assume that an 
increase in triiodothyronine levels observed exclusively 
in men receiving both thyroid hormones contributes 
to the improvement in sexual functioning. Unfortu-
nately, fluctuations in triiodothyronine concentrations 
may also explain why one patient had to prematurely 
terminate the study due to symptoms suggestive of 
hyperthyroidism. 
Despite the presence of correlations between sexual 
desire and the overall BDI-II score at baseline and dur-
ing treatment, combination therapy-induced improve-
ment in desire was not accompanied by changes in de-
pressive symptoms. Based on these results, it seems that 
depressive symptoms in young levothyroxine-treated 
men do not justify the introduction of levothyroxine/
liothyronine combination therapy. The obtained results 
suggest that the beneficial association of an improve-
ment in desire induced by levothyroxine/liothyronine 
and mood was probably counterbalanced by a neutral 
effect of other factors. In line with this explanation, the 
BDI-II score correlated with numerous other factors, 
including the body mass index and blood pressure, 
which remained unaltered during the study. Moreover, 
at least in the case of the body mass index, correlations 
with BDI-II were stronger than for desire. Certainly, it 
is possible that the combination therapy, at least at the 
daily doses used in the current study, does not fully 
restore adequate thyroid hormone levels in all brain 
structures playing a role in the regulation of well-being. 
There are some limitations of this study, the most 
important of which are the small number of participants 
and its short duration. Moreover, although well-validat-
ed, as in the case of other self-report inventories, the 
utility of IIEF-15 and BDI-II questionnaires is limited by 
their subjectivity. Furthermore, the question of whether 
levothyroxine/liothyronine combination therapy affects 
sexual functioning in levothyroxine-naïve men with 
uncorrected hypothyroidism remains open. Finally, 
because of mandatory salt iodisation, iodine intake 
in Poland is adequate [31]. It cannot be ruled out that 
iodine deficiency may modulate the impact of thyroid 
hormone replacement on sexual functioning.
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Conclusions
In conclusion, replacement of levothyroxine with 
levothyroxine/liothyronine combination therapy im-
proved sexual desire in biochemically euthyroid men 
with persistent symptoms of hypothyroidism and this 
effect correlated with treatment-induced increase in 
triiodothyronine levels. The obtained results suggest 
that this form of supplementary treatment may be help-
ful in men with hypoactive sexual desire disorder and 
a history of hypothyroidism. Because of the small sample 
size, our findings should be confirmed in a larger study.
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